HKSE:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited · HKSE · Healthcare · HKD · FY for 2024
Figures on this page computed 2026-11-07 17:38 UTC
Last close
n/aHKD
Market data
We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.
6.4xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- computed
- Computed from the filing for 2024
10.0%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
3.8%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
3.1%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
0.34Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- computed
What it pays out is the furthest below its sector's middle: 0.21 against 0.54 on the market's range.
Five bars, one line
lens 7 of 9Each against its own average
4 of 5 readExcept where said otherwise: Computed from the filing for 2024
- Sales1.44x
Its own average over 10 years, 51.93B.
- Profit0.98x
Its own average over 10 years, 2.90B.
- Free cash flow0.85x
Its own average over 10 years, 2.72B.
- Debt1.80x
Its own average over 10 years, 6.89B.
- Pricen/a
Its own average over 0 years. Market data
Debt is furthest from its own average, at 1.80 times.
It reports in CNY and trades in HKD. Nothing on this page is converted between the two.
The filed years, as a table
10Each line is 100 at 2015-12-31, the first year we hold.
| Filed year | Sales | Profit | Shares in issue |
|---|---|---|---|
| 2015-12-31 | 100.0 | 100.0 | 100.0 |
| 2016-12-31 | 104.8 | 116.0 | 108.6 |
| 2017-12-31 | 109.6 | 158.5 | 125.9 |
| 2018-12-31 | 220.8 | 264.6 | 125.9 |
| 2019-12-31 | 339.6 | 245.2 | 125.9 |
| 2020-12-31 | 322.5 | 224.2 | 125.9 |
| 2021-12-31 | 360.9 | 286.1 | 125.9 |
| 2022-12-31 | 370.1 | 305.0 | 125.9 |
| 2023-12-31 | 394.9 | 311.9 | 125.9 |
| 2024-12-31 | 392.1 | 218.1 | 125.9 |
How sales was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2024
- Reported in
- CNY
How profit was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2024
- Reported in
- CNY
How shares in issue was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2024
- Reported in
- CNY
Figures behind the shape
Growth
2.9%faster is higher, placed against 4,950 companies as of 2026-11-06
Five-year revenue growth rate2.9%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- computed
Five-year EPS growth rate-2.4%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- computed
One-year change in net income-30.1%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- computed
Returns on capital
10.0%higher is higher, placed against 5,089 companies as of 2026-11-06
Return on invested capital10.0%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
Return on equity7.9%
Net Income / Shareholders' Equity x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
Return on assets3.5%
Net Income / Total Assets x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
Margins
16.7%wider is higher, placed against 3,412 companies as of 2026-11-06
Gross margin16.7%
Gross Profit / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
Operating margin4.8%
Operating Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
Net margin3.8%
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
Free cash flow margin3.1%
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
Price
6.4xcheaper is higher, placed against 4,362 companies as of 2026-11-06
Price to earnings6.4x
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- computed
- Computed from the filing for 2024
Price to book0.5x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- computed
- Computed from the filing for 2024
- computed
- Computed from the filing for 2024
EV to EBITDA2.5x
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- computed
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
Price to sales ratio0.2x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- computed
- Computed from the filing for 2024
- Computed from the filing for 2024
Safety
0.34safer is higher, placed against 3,227 companies as of 2026-11-06
Debt to equity0.34
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
Current ratio1.48
Current Assets / Current Liabilities
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
Interest coverage8.6x
Operating Income / Interest Expense
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
Altman Z-Score1.96
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
What it pays out
79.4%more, and better covered, is higher, placed against 1,091 companies as of 2026-11-06
Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- computed
Payout ratio79.4%
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
Dividend cover ratio1.0x
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- computed
Share a finding
A link to the finding, not to you: it carries nothing about your account.